Navigation Links
Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
Date:6/19/2013

SAN DIEGO, June 19, 2013 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced positive top-line results from a human abuse liability (HAL) study for NKTR-181, a first-in-class, opioid analgesic molecule with a slow rate of entry into the brain.  This slow rate of entry is designed to reduce the euphoria that can lead to the abuse of and addiction to current opioid analgesics.1 In the study data being presented today, NKTR-181 was rated similar to placebo in "drug liking" and "feeling high" scores and had highly statistically significant lower "drug liking" scores and reduced "feeling high" scores as compared to oxycodone at all doses tested (p<0.0001).Prescription opioids are critical in the management of moderate-to-severe chronic pain.  However, the abuse and misuse of these opioids have led to a serious public health crisis.
HAL studies are clinical studies that assess the relative abuse potential of a medicine.  These studies are conducted in a non-dependent, recreational drug abuser population and are designed to predict how probable it is that a particular medicine will be attractive to abusers (i.e., "liked").  The primary endpoint for the NKTR-181 HAL study was drug-liking measured on a bi-polar visual analogue scale (VAS).  This endpoint is known to correlate most directly with a drug's potential for abuse.2

"It is clear that there is a pressing societal need for better and safer analgesics," said Dr. Lynn Webster, President of the American Academy of Pain Medicine and lead investigator for the study at CRI Lifetree. "We know that speed of entry into the br
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
5. Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
6. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
7. Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston
8. Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results
9. Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol
10. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
11. Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was ... in which he has overseen the company,s four facilities ... , and Costa Rica.  Mr. King joined Tegra ... sales, engineering and manufacturing experience in medical device businesses, ...
(Date:1/15/2014)... , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ... has fueled rapid growth of these markets. ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ... aspects in today,s growth in the pharmaceutical ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Global Pharm Holdings Group, Inc. (OTCBB: GPHG) ("Global ... integrated pharmaceutical company engaged in pharmaceutical-related products distribution, ... business through its subsidiaries in Anhui, Jilin, Guangdong ... 31, 2011, it completed the acquisition of the ...
... Fla., Nov. 4, 2011 China Nuvo Solar Energy, ... signed an agreement with Bluewater Surgical, Inc. to a ... for spine surgery, sports medicine, trauma surgery and more ... as an alternative to the high priced medical device ...
Cached Medicine Technology:Global Pharm Holdings Group, Inc. Completes Acquisition of Qingdao Likang Pharmaceutical Co., Ltd. 2Global Pharm Holdings Group, Inc. Completes Acquisition of Qingdao Likang Pharmaceutical Co., Ltd. 3China Nuvo Solar Energy, Inc. Announces Third-Party Distribution Agreement With Bluewater Surgical, Inc. 2China Nuvo Solar Energy, Inc. Announces Third-Party Distribution Agreement With Bluewater Surgical, Inc. 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... Asia,s largest private hospital and one of the world,s top ... allow prospective patients to anticipate the costs of treatment. Called ... over 40 medical procedures at the hospital. REALCOST is on ... ...
... - October is Breast,Cancer Awareness Month, FLUSHING, N.Y., ... York Hospital Queens:, WHO: Karen Karsif, M.D., Director ... well as other experts from The Cancer Center are,available ... importance,of early detection. New York Hospital Queens has services ...
... Sean Kimerling,Testicular Cancer Foundation (SKTCF) is pleased to announce ... partnership will help spread,the message to men and their ... self-examination. While the reason is unknown, the,incidence of testicular ... organization whose mission is to reach men,and their families ...
... care plans share some important elements, but Sen. ... result in higher overall health care,spending than Sen. ... health policy researcher., Thorpe, professor of health ... Health, is the author of two analyses that ...
... in 5 Americans lives with at least one disability, CDC ... 43 million Americans -- one in five people -- have ... Disease Control and Prevention. , And a new CDC study ... report fair or poor health at disproportionately higher rates than ...
... Opportunity to Address Critical Issues During ... National Breast Cancer Awareness Month, DALLAS, Oct. ... sole debate between vice presidential candidates Sen. Joe,Biden and Gov. ... suggested Ifill reserve time for an issue that is both ...
Cached Medicine News:Health News:Bumrungrad International Hospital Makes Treatment Costs Available to Public - Bumrungrad International Offers Free Online Access to Actual Costs of 45 Procedures 2Health News:Bumrungrad International Hospital Makes Treatment Costs Available to Public - Bumrungrad International Offers Free Online Access to Actual Costs of 45 Procedures 3Health News:Understanding Breast Cancer Risks & Management 2Health News:Men's Health Network Welcomes its Newest Member to its Nationwide Team, The Sean Kimerling Testicular Cancer Foundation 2Health News:Emory Health Policy Expert Weighs in on Candidates' Health Care Plans 2Health News:Emory Health Policy Expert Weighs in on Candidates' Health Care Plans 3Health News:Minorities With Disabilities Report Poorer Health 2Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Suggests Questions for Vice Presidential Debate 2
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
... The Zeus Scientific, Inc. ANA Screen ELISA test ... detect anti-nuclear antibodies (ANA) in human sera. When ... system is capable of detecting all ANAs commonly ... DNA (dsDNA), Jo-1, Sm, Sm/RNP, SSA, SSB, and ...
... Immuno Concepts manufactures slides that are ... technologist to decrease the number of pipetting ... patient sample dilutions on the slides. Ask ... procedure and these slides. These slide formats ...
... a patented HEp-2 cell line that has ... to SS-A/Ro autoantibodies, without affecting the other ... been published worldwide on the HEp-2000 ANA ... autoantibodies when used in place of standard ...
Medicine Products: